BIOFIRE® FILMARRAY® Pneumonia (PN) Panel at Chughtai Lab

BIOFIRE® FILMARRAY® Pneumonia (PN) Panel at Chughtai Lab

The BIOFIRE® FILMARRAY® Pneumonia (PN) Panel at Chughtai Lab represents a paradigm shift in the rapid diagnosis of lower respiratory tract infections. Pneumonia remains a leading cause of morbidity and mortality globally and in Pakistan. Traditional diagnostic methods, such as sputum culture and sensitivity, often take 48 to 72 hours to yield actionable results. This delay frequently leads to empirical, broad-spectrum antibiotic therapy, which may be ineffective or contribute to the growing crisis of antimicrobial resistance. The BIOFIRE® FILMARRAY® Pneumonia (PN) Panel utilizes advanced syndromic testing to identify 33 clinically relevant targets simultaneously, including 18 bacteria, 8 viruses, and 7 antimicrobial resistance genes, from a single patient sample. By delivering comprehensive results in approximately one hour, this state-of-the-art molecular diagnostic tool enables clinicians to make rapid, evidence-based treatment decisions, optimizing patient outcomes and supporting vital antimicrobial stewardship initiatives.

This molecular assay utilizes multiplex polymerase chain reaction (PCR) technology to detect and identify pathogens directly from lower respiratory tract specimens. Unlike conventional cultures that require viable organisms to grow over several days, PCR technology amplifies the genetic material (DNA or RNA) of the pathogens, allowing for the detection of even slow-growing, fastidious, or non-viable organisms. This is particularly beneficial for patients who have already initiated antibiotic therapy, which often sterilizes cultures and renders traditional diagnostic methods inconclusive. The panel evaluates key anatomical regions of the lower respiratory tract, including the trachea, bronchi, and pulmonary parenchyma, by analyzing secretions that originate from these areas. The diagnostic value of this panel lies in its ability to differentiate between bacterial and viral etiologies rapidly, allowing healthcare providers to discontinue unnecessary antibiotics in viral cases or target specific pathogens with precision.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation and sample collection are critical to ensuring the accuracy and diagnostic yield of the BIOFIRE® FILMARRAY® Pneumonia (PN) Panel at Chughtai Lab. Patients and healthcare providers should observe the following guidelines:

• No Fasting Required: There is no need for dietary restrictions or fasting prior to sample collection. Patients may continue to eat and drink normally.
• Medication History: Inform the clinical staff of any current or recent antibiotic, antiviral, or corticosteroid therapies, as this clinical context is essential for the interpreting pathologist.
• Sample Type Identification: The test is validated for specific lower respiratory tract specimens, including sputum (including induced sputum), endotracheal aspirates (ETA), and bronchoalveolar lavage (BAL) fluid (including mini-BAL).
• Sputum Collection Preparation: If providing a sputum sample, patients should rinse their mouth with water to minimize contamination with oral flora and saliva. Deep coughing is required to produce a true lower respiratory tract specimen rather than simple saliva.
• Clinical Supervision: For hospitalized or critically ill patients, endotracheal aspirates and bronchoalveolar lavage samples must be collected by qualified medical personnel using sterile techniques to prevent contamination.

During the Procedure

The procedure varies depending on whether the patient is providing a voluntary sputum sample or undergoing an invasive clinical collection procedure:

• Sputum Collection: The patient is provided with a sterile, leak-proof specimen container. Under the guidance of laboratory staff, the patient is instructed to take deep breaths and perform a deep cough to expectorate sputum directly into the container. The sample is immediately capped and labeled.
• Endotracheal Aspirate (ETA): For intubated patients in an intensive care setting, a trained clinician inserts a sterile suction catheter through the endotracheal tube into the trachea. A vacuum is applied to aspirate secretions into a sterile inline trap. The procedure takes only a few minutes and is performed under continuous monitoring.
• Bronchoalveolar Lavage (BAL): This is a specialized medical procedure performed by a pulmonologist. A flexible bronchoscope is passed through the airway into the lungs. A small volume of sterile saline is instilled into a specific lung segment and then suctioned back, collecting cells and pathogens from the alveolar space.
• Laboratory Processing: Once the specimen is received at the molecular diagnostics department of Chughtai Lab, a laboratory technologist prepares the sample. A small aliquot of the specimen is loaded into the BIOFIRE® FILMARRAY® pouch along with hydration and system buffers.
• The BioFire Run: The pouch is inserted into the BIOFIRE® instrument. The automated system performs sample preparation, nucleic acid extraction, nested multiplex PCR amplification, and high-resolution melting curve analysis to detect the specific genetic signatures of the targets. The entire automated run takes approximately one hour.
• Safety and Comfort: Sputum collection is non-invasive and painless. ETA and BAL procedures may cause temporary discomfort or coughing, but they are performed under appropriate sedation or local anesthesia in a controlled clinical environment to ensure patient safety.

When is a BIOFIRE® FILMARRAY® Pneumonia (PN) Panel Performed?

Severe Community-Acquired Pneumonia (CAP)

Physicians request this panel when a patient presents with severe symptoms of community-acquired pneumonia, such as high fever, productive cough, severe dyspnea, and chest pain, accompanied by radiographic evidence of pulmonary infiltrates. Rapid identification of the causative pathogen is critical in severe cases to initiate targeted therapy immediately, reducing the risk of complications such as respiratory failure, sepsis, or empyema.

Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP)

Patients who develop pneumonia after being hospitalized for more than 48 hours (HAP) or those on mechanical ventilation (VAP) are at high risk for infections caused by multidrug-resistant (MDR) pathogens. The BIOFIRE® FILMARRAY® Pneumonia (PN) Panel is highly valuable in these settings because it detects difficult-to-culture bacteria and critical antimicrobial resistance genes, allowing clinicians to tailor antibiotic regimens within hours rather than days.

Immunocompromised Patients with Respiratory Symptoms

Individuals with compromised immune systems, such as oncology patients undergoing chemotherapy, transplant recipients on immunosuppressive therapy, or patients with advanced HIV, are susceptible to atypical and opportunistic pathogens. This panel provides a comprehensive screen that includes atypical bacteria and viral pathogens, helping physicians quickly differentiate between viral pneumonitis and bacterial infections, which require vastly different therapeutic approaches.

Unresolved Lower Respiratory Tract Infections

When a patient fails to respond to initial empirical antibiotic therapy, it suggests either a viral etiology, an atypical pathogen not covered by standard antibiotics, or infection with a resistant bacterial strain. The BIOFIRE® FILMARRAY® Pneumonia (PN) Panel assists the clinical team by identifying the exact pathogen and detecting resistance markers, explaining the treatment failure and guiding the selection of an effective alternative drug.

Rapid Antimicrobial Stewardship and De-escalation

In modern healthcare, preventing the overuse of broad-spectrum antibiotics is a critical priority. Clinicians order this rapid panel to implement antimicrobial stewardship. If the panel detects a viral pathogen without any bacterial targets or resistance markers, the clinical team can confidently de-escalate or discontinue unnecessary antibiotic therapy, minimizing side effects, reducing healthcare costs, and preventing the selection of resistant organisms.

What Does a BIOFIRE® FILMARRAY® Pneumonia (PN) Panel Detect?

The BIOFIRE® FILMARRAY® Pneumonia (PN) Panel is designed to detect a broad spectrum of pathogens and genetic markers associated with lower respiratory tract infections. The panel identifies the following targets:

• Acinetobacter calcoaceticus-baumannii complex: A common cause of healthcare-associated infections, particularly in intensive care units, often associated with multidrug resistance.
• Enterobacter cloacae complex: An opportunistic Gram-negative bacterium that can cause severe nosocomial pneumonia.
• Escherichia coli: A Gram-negative bacillus that, while less common in community-acquired cases, can cause severe hospital-acquired pneumonia.
• Haemophilus influenzae: A major cause of community-acquired pneumonia, particularly in pediatric populations and patients with chronic obstructive pulmonary disease (COPD).
• Klebsiella aerogenes: An opportunistic pathogen frequently associated with nosocomial infections and antibiotic resistance.
• Klebsiella oxytoca: A Gram-negative bacterium capable of causing severe lobar pneumonia, particularly in debilitated individuals.
• Klebsiella pneumoniae group: A significant cause of severe, necrotizing pneumonia characterized by a high risk of systemic dissemination.
• Moraxella catarrhalis: A common respiratory pathogen that frequently causes exacerbations in patients with pre-existing lung disease.
• Proteus species: Gram-negative bacilli that can cause severe respiratory infections in hospitalized patients.
• Pseudomonas aeruginosa: A highly aggressive pathogen common in ventilator-associated pneumonia, known for its intrinsic resistance to many antibiotics.
• Serratia marcescens: An opportunistic pathogen that can cause healthcare-associated respiratory tract infections.
• Staphylococcus aureus: A major bacterial pathogen capable of causing severe, necrotizing pneumonia, often following influenza infection.
• Streptococcus pneumoniae: The most common bacterial cause of community-acquired pneumonia across all age groups.
• Streptococcus pyogenes: Also known as Group A Streptococcus, a rare but highly virulent cause of severe pneumonia and empyema.
• Streptococcus agalactiae: Group B Streptococcus, which can cause pneumonia in newborns and immunocompromised adults.
• Chlamydia pneumoniae: An atypical bacterium responsible for mild to moderate community-acquired respiratory infections.
• Legionella pneumophila: The causative agent of Legionnaires’ disease, a severe form of pneumonia associated with environmental water sources.
• Mycoplasma pneumoniae: A common atypical bacterium that causes “walking pneumonia,” particularly in young adults and school-aged children.
• Adenovirus: A double-stranded DNA virus that can cause severe respiratory infections, particularly in closed populations and immunocompromised hosts.
• Coronavirus: Detects endemic human coronaviruses (excluding SARS-CoV-2, which is covered by other specific assays).
• Human Metapneumovirus: A common viral pathogen causing upper and lower respiratory tract infections in pediatric and elderly populations.
• Human Rhinovirus/Enterovirus: Highly prevalent viruses that can trigger severe asthma and COPD exacerbations or progress to pneumonia.
• Influenza A and Influenza B: Major seasonal viral pathogens associated with high morbidity, secondary bacterial infections, and severe respiratory complications.
• Parainfluenza Virus: A group of viruses causing croup, bronchitis, and pneumonia, particularly in children.
• Respiratory Syncytial Virus (RSV): A leading cause of bronchiolitis and pneumonia in infants and vulnerable older adults.
• mecA/C and MREJ: Genetic markers that confer methicillin resistance in Staphylococcus aureus (MRSA), critical for directing therapy away from standard beta-lactams.
• KPC (Klebsiella pneumoniae carbapenemase): A resistance gene conferring resistance to carbapenem antibiotics, representing a severe therapeutic challenge.
• NDM (New Delhi metallo-beta-lactamase): A highly resistant gene that inactivates almost all beta-lactams, including carbapenems.
• OXA-48-like: A carbapenemase gene common in Enterobacteriaceae, limiting treatment options.
• CTX-M: A gene encoding extended-spectrum beta-lactamases (ESBLs), rendering cephalosporins ineffective.
• VIM and IMP: Metallo-beta-lactamase genes that confer resistance to carbapenems, requiring alternative, often toxic, antibiotic regimens.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing rapid and highly accurate diagnostic services. Because the BIOFIRE® FILMARRAY® Pneumonia (PN) Panel is a critical test for acute and often life-threatening infections, the laboratory prioritizes its processing. Once the sample reaches the molecular diagnostics department, the testing process takes approximately one hour. The final verified report is typically available within a few hours of sample receipt, depending on transport times from various collection centers. Patients and referring physicians can access reports instantly through the Chughtai Lab mobile application, the official online portal, or via automated WhatsApp delivery. This rapid turnaround time ensures that critical clinical decisions, such as initiating targeted antibiotics or de-escalating therapy, can be made without delay.

BIOFIRE® FILMARRAY® Pneumonia (PN) Panel Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Bacterial Pathogens (Semi-Quantitative)	Not Detected	Detection of specific bacteria (e.g., S. pneumoniae, P. aeruginosa) reported in genomic copies/mL (10^4 to 10^7+), indicating colonization or active infection.
Atypical Bacteria (Qualitative)	Not Detected	Detection of Mycoplasma pneumoniae, Legionella pneumophila, or Chlamydia pneumoniae, confirming atypical pneumonia.
Viral Pathogens (Qualitative)	Not Detected	Detection of Influenza A/B, RSV, Adenovirus, or Rhinovirus, indicating primary viral pneumonia or viral-bacterial co-infection.
Methicillin Resistance Markers	Not Detected	Detection of mecA/C and MREJ, confirming the presence of Methicillin-Resistant Staphylococcus aureus (MRSA).
Carbapenemase Resistance Genes	Not Detected	Detection of KPC, NDM, OXA-48-like, VIM, or IMP, indicating resistance to carbapenem antibiotics.
ESBL Resistance Genes	Not Detected	Detection of CTX-M, indicating resistance to third-generation cephalosporins.
Specimen Quality Control	Passed / Valid	Failed run, indicating presence of PCR inhibitors, inadequate sample volume, or technical error requiring a repeat test.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for BIOFIRE® FILMARRAY® Pneumonia (PN) Panel?

• Experienced Healthcare Professionals: Our molecular diagnostics department is staffed by highly trained pathologists, microbiologists, and laboratory technologists specializing in advanced PCR assays.
• Patient-Focused Care: We prioritize patient comfort and safety during sample collection and provide clear guidance throughout the diagnostic process.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control standards, ensuring the highest accuracy and reliability for molecular testing.
• Professional Reporting: Reports are detailed, clear, and structured to provide clinicians with immediate, actionable information regarding pathogens and resistance genes.
• Modern Diagnostic Approach: We utilize state-of-the-art BIOFIRE® FILMARRAY® technology to deliver comprehensive syndromic testing for rapid clinical intervention.
• Comfortable Environment: Our diagnostic centers and collection points are designed to provide a clean, hygienic, and welcoming environment for all patients.
• Convenient Location: With an extensive network of collection centers across Pakistan, patients can easily access our high-end diagnostic services.
• Commitment to Accurate Diagnosis: We are dedicated to supporting clinical decision-making and antimicrobial stewardship by providing rapid, evidence-based diagnostic results.